Harvard Bioscience (NASDAQ:HBIO) CEO Purchases $25,050.00 in Stock

Harvard Bioscience, Inc. (NASDAQ:HBIO) CEO John Duke purchased 5,000 shares of Harvard Bioscience stock in a transaction on Monday, March 16th. The shares were acquired at an average cost of $5.01 per share, for a total transaction of $25,050.00. Following the completion of the transaction, the chief executive officer owned 105,000 shares of the company’s stock, valued at $526,050. This represents a 5.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Harvard Bioscience Trading Down 2.8%

HBIO traded down $0.14 during trading on Tuesday, hitting $4.87. 81,266 shares of the company’s stock were exchanged, compared to its average volume of 46,616. Harvard Bioscience, Inc. has a 1 year low of $2.81 and a 1 year high of $9.50. The stock has a 50 day moving average price of $5.67 and a 200 day moving average price of $5.66. The firm has a market cap of $21.78 million, a P/E ratio of -3.80 and a beta of 1.51.

Hedge Funds Weigh In On Harvard Bioscience

A number of institutional investors have recently added to or reduced their stakes in HBIO. Weber Capital Management LLC ADV acquired a new stake in shares of Harvard Bioscience during the fourth quarter valued at about $2,140,000. Corsair Capital Management L.P. lifted its stake in shares of Harvard Bioscience by 1,008.7% in the fourth quarter. Corsair Capital Management L.P. now owns 1,108,692 shares of the medical instruments supplier’s stock worth $741,000 after acquiring an additional 1,008,692 shares in the last quarter. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Harvard Bioscience in the fourth quarter worth about $401,000. AMH Equity Ltd boosted its holdings in Harvard Bioscience by 15.4% in the third quarter. AMH Equity Ltd now owns 4,047,535 shares of the medical instruments supplier’s stock valued at $1,775,000 after purchasing an additional 538,832 shares during the last quarter. Finally, Meros Investment Management LP boosted its holdings in Harvard Bioscience by 32.6% in the fourth quarter. Meros Investment Management LP now owns 1,217,628 shares of the medical instruments supplier’s stock valued at $814,000 after purchasing an additional 299,369 shares during the last quarter. Institutional investors and hedge funds own 80.87% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on HBIO shares. Zacks Research upgraded Harvard Bioscience to a “hold” rating in a report on Thursday, December 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Harvard Bioscience in a research report on Monday, December 29th. Benchmark lowered their target price on Harvard Bioscience from $20.00 to $6.00 and set a “speculative buy” rating for the company in a research note on Friday. Wall Street Zen upgraded Harvard Bioscience from a “hold” rating to a “buy” rating in a report on Monday, November 17th. Finally, New Street Research set a $6.00 price target on Harvard Bioscience in a research report on Friday. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $6.00.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.